NEW YORK (GenomeWeb News) – Roche today said that med fusion, a Lewisville, Texas-based clinical lab and clinical trials services firm, has been named a Roche Molecular Center of Excellence for the next five years.
As part of the designation, med fusion will offer a range of Roche's molecular technologies including the cobas 4800 V600 Mutation Test, a companion diagnostic approved by the US Food and Drug Administration last year for identifying patients who are eligible for treatment with the drug Zelboraf (vemurafenib) for inoperable or metastatic melanoma.
According to Roche, med fusion is one of 35 labs in the US and three in Texas to be named a Roche MCOE. "We value their expertise and look forward to working together in implementing molecular technologies in the advancement of personalized medicine," Whitney Green, SVP of molecular diagnostics at Roche Diagnostics, said in a statement.